This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF (CORRAL-AF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04684212
Recruitment Status : Not yet recruiting
First Posted : December 24, 2020
Last Update Posted : November 18, 2023
Sponsor:
Collaborator:
Lifetech Scientific (Shenzhen) Co., Ltd.
Information provided by (Responsible Party):
Brian O'Neill MD, Henry Ford Health System

Brief Summary:
The primary objective is to demonstrate the safety and efficacy of the implantation of the LAmbre PlusTM device in patients with large or irregularly shaped appendages with non-valvular atrial fibrillation who are at increased risk for stroke and systemic embolism compared to oral anticoagulation (OAC).

Condition or disease Intervention/treatment Phase
Atrial Fibrillation Left Atrial Appendage Thrombosis CVA Device: LAmbre PlusTM Left Atrial Appendage Closure System Drug: Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa) Not Applicable

Detailed Description:

This prospective, randomized, multicenter study will enroll 2,931 subjects (2706 randomized subjects, 225 roll-in subjects) at up to 75 investigational sites in the United States. Patients presenting with non-valvular atrial fibrillation who are at increased risk for stroke and systemic embolism based on CHA2DS2-VASc scores, and who are recommended for oral anticoagulation therapy but have an appropriate rationale to seek a non-pharmacologic alternative to oral anticoagulation, and who meet all eligibility criteria will be enrolled in the study.

Subjects will have clinical follow-up in-hospital and at 45 days, 6 months, 12 months, and annually up to 5-years. CT/Imaging or Transesophageal echocardiographic (TEE) follow-up will occur at 45 days and TEE at 1-year.

The LAmbre PlusTM Left Atrial Appendage (LAA) Closure System is intended to reduce the risk of thromboembolism from the left atrial appendage (LAA) in patients with nonvalvular atrial fibrillation who:

  • Are at increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores and are recommended for oral anticoagulation (OAC) therapy; AND
  • Are deemed by their physician to be suitable for OAC; AND
  • Have an appropriate rationale to seek a non-pharmacological alternative to OAC, taking into account the safety and effectiveness of the device compared to OAC

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2931 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This prospective, randomized, multicenter study will enroll 2,931 subjects (2706 randomized subjects, 225 roll-in subjects) at up to 75 investigational sites in the United States.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF: The CORRAL-AF Study
Estimated Study Start Date : December 1, 2023
Estimated Primary Completion Date : December 1, 2028
Estimated Study Completion Date : December 1, 2033

Arm Intervention/treatment
Experimental: Device Arm
The LAmbre PlusTM Left Atrial Appendage Closure System (LAmbre device)
Device: LAmbre PlusTM Left Atrial Appendage Closure System
The LAmbre Plus device is a self-expanding occluder, composed of a distal Umbrella and a proximal Cover laser welded together, delivered percutaneously via femoral venous access and trans-septal puncture. The distal Umbrella consists of an elastic nitinol frame and outer PET membrane, and has circumferential anchors to secure the occluder to the left atrial appendage (LAA) wall. The proximal Cover is a disc of elastic nitinol mesh, which seals the orifice of the LAA and minimizes thrombus formation, and includes a PET membrane to prevent the passage of blood into the LAA after implantation.
Other Name: LAmbre device

Active Comparator: Control Arm
Market approved oral anticoagulation (OAC)
Drug: Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
Continuation of market approved OAC drug.
Other Name: OAC

Roll-in Arm
225 roll-in subjects
Device: LAmbre PlusTM Left Atrial Appendage Closure System
The LAmbre Plus device is a self-expanding occluder, composed of a distal Umbrella and a proximal Cover laser welded together, delivered percutaneously via femoral venous access and trans-septal puncture. The distal Umbrella consists of an elastic nitinol frame and outer PET membrane, and has circumferential anchors to secure the occluder to the left atrial appendage (LAA) wall. The proximal Cover is a disc of elastic nitinol mesh, which seals the orifice of the LAA and minimizes thrombus formation, and includes a PET membrane to prevent the passage of blood into the LAA after implantation.
Other Name: LAmbre device




Primary Outcome Measures :
  1. Composite of time to first occurrence of stroke, cardiovascular death, or clinically relevant major or non-major bleeding events [ Time Frame: through study completion, up to 5 years ]
    Defined as composite of: First occurrence of stroke defined by NeuroARC; Cardiovascular death defined as any death due to proximate cause (e.g., MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, and all procedure related deaths, including those related to concomitant treatment; Clinically relevant major or non-major bleeding events defined by hemoglobin of ≥2.0 g/dl during a 24-h period, transfusion of ≥2 units of packed red cells, bleeding at a critical site (intracranial, intraspinal, intraocular, pericardial, intramuscular with compartment syndrome, or retroperitoneal), or fatal bleeding

  2. Composite of time to first occurrence of ischemic stroke or systemic embolism [ Time Frame: through study completion, up to of 5 years ]
    Defined as composite of: First occurrence of ischemic stroke defined by NeuroARC; Systemic embolization defined as acute vascular insufficiency or occlusion of the extremities or any non-CNS organ associated with clinical, imaging, surgical/autopsy evidence of arterial occlusion in the absence of other likely mechanism (e.g. trauma, atherosclerosis, or instrumentation). When there is presence of prior peripheral artery disease, angiographic or surgical or autopsy evidence is required to show abrupt arterial occlusion.

  3. Overall safety [ Time Frame: 12 months ]
    Overall safety is defined as the composite of: Major procedure-related complications, defined as the composite of cardiac perforation, pericardial effusion with tamponade, device embolization, and major vascular complications (adjudicated by the independent Clinical Events Committee as related to the study device or procedure); AND Major adverse events, defined as all death, all stroke and major bleeding as compared to OAC


Secondary Outcome Measures :
  1. Mortality [ Time Frame: 45 days, 6 months, 12 months, 5 years ]
    Death classified as cardiovascular or non-cardiovascular and reported cumulatively and individually

  2. Myocardial Infarction [ Time Frame: 45 days, 6 months, 12 months, 5 years ]
    Occurrence of MI defined by modified Third Universal Definition, which will be adjudicated and classified by an independent Clinical Events Committee (CEC)

  3. Peri-Procedural Stroke [ Time Frame: 30 days ]
    Occurrence of peri-procedural stroke defined as Overt CNS Injury (NeuroARC defined)

  4. Bleeding Complications [ Time Frame: 45 days, 6 months, 12 months, 5 years ]
    Occurrence of bleeding complications evaluated as major bleeding (BARC Type ≥3); major and minor bleeding (BARC ≥2) and its components by BARC Type

  5. Major Procedure-Related Complications [ Time Frame: 45 days ]
    Occurrence of major procedure-related complications, defined as the composite of cardiac perforation, pericardial effusion with tamponade, ischemic stroke (NeuroARC defined), device embolization, major vascular complications (VARC 3 defined), and major bleeding

  6. Vascular Complications [ Time Frame: 45 days, 6 months, 12 months, 5 years ]
    Occurrence of Vascular complications (VARC 3 defined)

  7. Embolic events [ Time Frame: 45 days, 6 months, 12 months, 5 years ]
    Occurrence of embolic events, defined as the composite of ischemic stroke (NeuroARC defined) and systemic embolization

  8. Ischemic Stroke [ Time Frame: 45 days, 6 months, 12 months, 5 years ]
    Occurrence of ischemic stroke (NeuroARC defined)

  9. Systemic embolization [ Time Frame: 45 days, 6 months, 12 months, 5 years ]
    Occurrence of systemic embolization defined by acute vascular insufficiency or occlusion of the extremities or any non-CNS organ associated with clinical, imaging, surgical/autopsy evidence of arterial occlusion in the absence of other likely mechanism (e.g. trauma, atherosclerosis, or instrumentation). When there is presence of prior peripheral artery disease, angiographic or surgical or autopsy evidence is required to show abrupt arterial occlusion.

  10. All CNS injury and dysfunction [ Time Frame: 45 days, 6 months, 12 months, 5 years ]
    Occurrence of all CNS injury and dysfunction (NeuroARC defined)

  11. Technical success [ Time Frame: within 24 hours Post-procedure ]
    Technical success is defined as successful implantation (acceptable device position, stability, and LAA seal) with the assigned device

  12. Closure success [ Time Frame: 45 days ]
    Closure success is defined as technical success followed by successful LAA closure (complete LAA closure or peri-device residual jet <5 mm in width by TEE/Imaging or CT)

  13. Procedural Success [ Time Frame: 7 days Post-procedure ]
    Procedural success is defined as technical success without major procedure-related complications

  14. Total Procedural Time [ Time Frame: within 24 hours Post-procedure ]
    Total procedural time is defined as time elapsed between first venous access and removal of the last catheter from the venous access sheath

  15. Device Thrombosis [ Time Frame: 45 days, 6 months, 12 months, 5 years ]
    Occurrence of device thrombosis



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Potential subjects must meet ALL of the following criteria to be eligible for inclusion in the study:

Inclusion Criteria:

  1. The patient is a male or non-pregnant female ≥18 years of age
  2. The patient has documented paroxysmal, persistent, or permanent non-valvular atrial fibrillation or flutter
  3. The patient has a CHADS2 score ≥ 2 or a CHA2DS2-VASc score of ≥ 3, and is recommended for oral anticoagulation therapy
  4. The patient is deemed by their physician to be suitable for short-term OAC, but there is an appropriate rationale for seeking a non-pharmacologic alternative to oral anticoagulation
  5. The patient is deemed suitable for LAA closure in a shared decision model with a non-implanting physician
  6. The patient is willing and able to comply with protocol-specified treatment and follow-up evaluations
  7. The patient (or his or her legally authorized representative) has been informed of the nature of the study, agrees to its provisions, and has been provided written informed consent approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC)

Potential subjects will be excluded if ANY of the following conditions apply:

Exclusion Criteria:

  1. Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year following index procedure. Female patients of childbearing potential must have a negative pregnancy test done within 7 days prior to index procedure per site standard test
  2. Patients with atrial fibrillation that is defined by a single occurrence, or that is transient or reversible (e.g., secondary to CABG, an interventional procedure, pneumonia, or hyperthyroidism)
  3. Patients who require long-term anticoagulation/DAPT for a condition other than atrial fibrillation
  4. Patients not suitable for short term oral anti-coagulation (including due to bleeding diathesis or coagulopathy or absolute contraindication to OAC or DAPT ) or who will refuse transfusion
  5. Patients with rheumatic mitral valve disease, known severe aortic stenosis requiring surgical or percutaneous valve replacement, or existing mechanical valve prosthesis
  6. Active infection with bacteremia
  7. Known hypersensitivity or contraindication to aspirin, clopidogrel, heparin/bivalirudin, any device material or component (nitinol, nickel, titanium, PET), and/or contrast sensitivity that cannot be adequately pre-medicated
  8. Anatomic conditions that would prevent performance of the LAA occlusion procedure (e.g., prior atrial septal defect [ASD] or patient foramen ovale [PFO] surgical repair or implanted closure device, or obliterated left atrial appendage)
  9. Recent (within 30 days pre-procedure) or planned (within 60 days post procedure) cardiac or non-cardiac interventional or surgical procedure (e.g., cardioversion, ablation, percutaneous coronary intervention, cataract surgery, etc.)
  10. Recent (within 90 days pre-procedure) stroke, transient ischemic attack, or myocardial infarction
  11. Severe heart failure (New York Heart Association Class IV)
  12. Known asymptomatic carotid artery disease with>70% diameter stenosis OR symptomatic carotid disease (>50% diameter stenosis with ipsilateral stroke or TIA). Subjects with prior carotid endarterectomy or carotid stent placement may be enrolled, provided that known diameter stenosis is <50%.
  13. Past or pending heart or any other organ transplant, or on the waiting list for any organ transplant
  14. Current participation in another investigational drug or device study
  15. Size of the left atrial appendage at the LAmbre Plus defined landing zone within outside the manufactures recommendations (Table 2.)
  16. Patients with an indication for chronic P2Y12 platelet inhibition therapy
  17. Patients who are unable to undergo CT scan

Echocardiographic Exclusion Criteria

  1. Left atrial appendage anatomy may accommodate implantation of the WATCHMAN device, according to IFU by size.
  2. LVEF <25%
  3. Intracardiac thrombus or dense spontaneous echo contrast, as visualized by TEE within 2 days prior to implant
  4. Presence of a high-risk patent foramen ovale (PFO), defined as an atrial septal aneurysm (excursion >15 mm or length >15 mm) or large shunt (early, within 3 beats and/or substantial passage of bubbles)
  5. Moderate or severe mitral valve stenosis (mitral valve area <1.5 cm2)
  6. Complex atheroma with mobile plaque of the descending aorta and/or aortic arch (Grade 4 or higher)
  7. Presence of an intracardiac tumor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04684212


Contacts
Layout table for location contacts
Contact: Brian O'Neill, MD 313-916-8708 boneil3@hfhs.org
Contact: Stephen Krafchak, MS 313-916-3571 skrafch1@hfhs.org

Locations
Layout table for location information
United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48202
Contact: Stephen Krafchak, MS    313-916-3571      
Principal Investigator: Brian O'Neill, MD         
Sponsors and Collaborators
Brian O'Neill MD
Lifetech Scientific (Shenzhen) Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Brian O'Neill, MD Henry Ford Health System
Publications:
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction; Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S; ESC Committee for Practice Guidelines (CPG). Third universal definition of myocardial infarction. Eur Heart J. 2012 Oct;33(20):2551-67. doi: 10.1093/eurheartj/ehs184. Epub 2012 Aug 24. No abstract available.

Layout table for additonal information
Responsible Party: Brian O'Neill MD, Director of Interventional Cardiology Research, Henry Ford Health System
ClinicalTrials.gov Identifier: NCT04684212    
Other Study ID Numbers: G-200316
First Posted: December 24, 2020    Key Record Dates
Last Update Posted: November 18, 2023
Last Verified: November 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by Brian O'Neill MD, Henry Ford Health System:
LAMBRE device
Left Atrial Appendage Occlusion device
CVA prevention
Atrial Fibrillation
Cardiovascular angiography
Anti-coagulation management
Thromboembolism
nonvalvular atrial fibrillation
non-pharmacological alternative
Thrombosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Thrombosis
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Embolism and Thrombosis
Vascular Diseases
Warfarin
Rivaroxaban
Dabigatran
Edoxaban
Apixaban
Betrixaban
Anticoagulants
Factor Xa Inhibitors
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action